Results

1–9 of 9 results for AREDS

New Data Analyses on Whether AREDS Patients Should Have Routine Genetic Testing
Stephen R. Kaufman, MD
Annual Meeting Talks
2025
Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights From thePhase 3 OAKS and DERBY Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2025
The Updated AREDS Simplified Severity Scale for Age-Related Macular Degeneration, Incorporating Reticular Pseudodrusen
Tiarnan D Keenan, BM BCh, PhD
Updates from the Field
2024
Artificial Intelligence Algorithm May Improve Performance of Retinal Specialists in Detection of Retinal Fluid on OCT in AMD: AREDS2 10-Year Study
Michael J. Elman, MD
Annual Meeting Talks
2020
Ten-Year Follow-up Data From the AREDS2 Study
Emily Y. Chew, MD
Updates from the Field
2021
Interaction of Genotypes and AREDS Formulation Use in the Development of Neovascular AMD
Pradeepa Yoganathan, MSc, MD, FRCS(C)
Updates from the Field
2019
Interaction of Genotypes and AREDS Formulation Use in the Development of Neovascular AMD
Pradeepa Yoganathan, MSc, MD, FRCS(C)
Annual Meeting Talks
2019
Interaction of Genotypes and AREDS Formulation Use in the Development of Neovascular AMD
Updates from the Field
Treatment Response to Antioxidant Supplementation Based on CFH and ARMS2Â Genetic Risk Allele Number in AREDS Patients With No AMD at Baseline
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2016